Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to evaluate whether treatment with intravitreal ranibizumab is associated with improvement (i.e. reduction at Day 90 from Baseline) in central subfield retinal thickness (CSRT) as determined by spectral domain/high definition optical coherence tomography (SD/HD-OCT) after 3 monthly injections of ranibizumab. The CSRT represents the average retinal thickness (μm) of the circular area within 1 mm diameter around the foveal center.
Critère d'inclusion
- Visual impairment due to neovascular AMD